for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc (ADR)

GSK

Latest Trade

41.64USD

Change

-0.26(-0.62%)

Volume

4,966,889

Today's Range

41.61

 - 

42.38

52 Week Range

38.43

 - 

48.25

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
41.90
Open
41.89
Volume
4,966,889
3M AVG Volume
60.92
Today's High
42.38
Today's Low
41.61
52 Week High
48.25
52 Week Low
38.43
Shares Out (MIL)
4,989.60
Market Cap (MIL)
106,500.70
Forward P/E
--
Dividend (Yield %)
4.86

Next Event

GlaxoSmithKline PLC at Credit Suisse Global Healthcare Conference

Latest Developments

More

GSK, Clover To Evaluate COVID-19 Vaccine Candidate With Pandemic Adjuvant System

Immatics And GSK Partner To Develop Novel Adoptive Cell Therapies

FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc (ADR)

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Contact Info

G S K House, 980 Great West Road

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

38.9K

2018

41.1K

2019

43.1K

2020(E)

45.5K
EPS (USD)

2017

2.910

2018

3.104

2019

3.161

2020(E)

3.020
Price To Earnings (TTM)
17.49
Price To Sales (TTM)
2.45
Price To Book (MRQ)
6.76
Price To Cash Flow (TTM)
9.99
Total Debt To Equity (MRQ)
254.57
LT Debt To Equity (MRQ)
196.85
Return on Investment (TTM)
12.32
Return on Equity (TTM)
7.65

Latest News

Latest News

BRIEF-GSK Says Filing Accepted By EMA For Trelegy Ellipta Use In Adult Patients With Asthma

* GSK FILING ACCEPTED BY EUROPEAN MEDICINES AGENCY FOR TRELEGY ELLIPTA USE IN ADULT PATIENTS WITH ASTHMA

BRIEF-Gsk Says Collaboration Launched To Develop Treatment Regimens For Tuberculosis

* GSK SAYS GLOBAL COLLABORATION LAUNCHED TO DEVELOP TREATMENT REGIMENS FOR TUBERCULOSIS

BRIEF-GSK Says EMA Accepted Submission Of Co's Marketing Authorisation Application For Zejula (Niraparib)

* EUROPEAN MEDICINES AGENCY ACCEPTS SUBMISSION OF GSK'S MARKETING AUTHORISATION APPLICATION FOR ZEJULA (NIRAPARIB) IN FIRST-LINE MAINTENANCE TREATMENT FOR WOMEN WITH PLATINUM-RESPONSIVE ADVANCED OVARIAN CANCER

Exclusive: Germany's Stada buys 15 GSK consumer health brands

Private equity-backed generic drugmaker Stada <STAGn.D> said it has agreed to buy 15 consumer healthcare products from British drugmaker GlaxoSmithKline <GSK.L> to further strengthen its prescription-free drugs business in Europe.

UPDATE 1-China's Clover in research venture with GSK on coronavirus vaccine candidate

China's Clover Biopharmaceuticals said https://www.businesswire.com/news/home/20200224005319/en on Monday it will work with Britain's GlaxoSmithKline on a research tie-up that will develop the Chinese company's protein-based coronavirus vaccine candidate "COVID-19 S-Trimer".

China's Clover partners with GSK on coronavirus vaccine candidate

China's Clover Biopharmaceuticals said https://www.businesswire.com/news/home/20200224005319/en on Monday it had entered into a research tie-up with Britain's GlaxoSmithKline for its protein-based coronavirus vaccine candidate "COVID-19 S-Trimer".

GSK profit falls short as cheap competition hits older drugs

GlaxoSmithKline <GSK.L> missed fourth-quarter earnings forecasts on Wednesday as cheap competition to the British drugmaker's respiratory medicines offset strong growth in sales of its shingles vaccine.

GSK fourth-quarter profit misses estimates, initiates plan to split into two

GlaxoSmithKline Plc's quarterly profit fell short of analysts' expectations on Wednesday, and the drugmaker said it has begun its planned split into two companies following the merger of its over-the-counter products into a venture with Pfizer.

EU court sets criteria for GSK case on 'pay-for-delay' drug deals

The European Union's top court set criteria on Thursday to resolve a dispute in Britain over deals GlaxoSmithKline <GSK.L> struck with rival drugmakers to delay the launch of generic drugs.

GSK appeal against fine over 'pay-for-delay' drug deals faces EU rebuke

British drugmaker GlaxoSmithKline may have harmed competition with payments it made to generic drugmakers to delay the launch of cheap copies of an antidepressant, according to an adviser to the European Court of Justice.

Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs

Drugmakers including Pfizer Inc <PFE.N>, GlaxoSmithKline PLC <GSK.L> and Sanofi SA <SASY.PA> are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.

How a seven-month-old Supreme Court ruling revived a nine-year-old case against GSK

In December 2017, U.S. District Judge Cynthia Rufe of Philadelphia seemingly drove a stake through the heart of litigation by two employee healthcare funds suing GlaxoSmithKline over its marketing of the diabetes drug Avandia. The plans, which sued back in 2010, alleged...

U.S. FDA declines to approve GSK drugs division's long acting HIV injection

GlaxoSmithKline's HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection.

Britain's GSK seeks U.S approval for rival to J&J's multiple myeloma drug

GlaxoSmithKline said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson and Genmab's Darzalex.

GSK seeks FDA approval for investigational HIV treatment

GlaxoSmithKline Plc said on Thursday its HIV unit has submitted a new drug application to the U.S. Food and Drug Administration seeking approval for fostemsavir, an experimental treatment for HIV in adults.

GSK sees breakthrough in shingles vaccine output in 2024

GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.

GSK eyes 'step change' in shingles vaccine output in 2024

GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a "step change" in production.

Merck KGaA raises 2019 guidance after Versum takeover

German science and technology company Merck KGaA <MRCG.DE> raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials <VSM.N> in October.

GSK settles with insurers over 'egregious' drug manufacturing issues

GlaxoSmithKline PLC on Tuesday said it had reached an eve-of-trial settlement resolving claims by several insurers that it misled them into paying $2.7 billion for drugs made at a Puerto Rico plant in an "egregious" violation of federal manufacturing standards.

GSK faces multibillion-dollar trial with plaintiffs' lawyer Lanier by its side

GlaxoSmithKline Plc is set to face trial on Tuesday in a multibillion-dollar lawsuit alleging it misled insurers into paying for drugs made in "egregious" violation of federal quality standards, with a lawyer better known for securing big verdicts against drugmakers leading...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up